Abstract
Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to a steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. Up-date, PPAR-γ is expressed in various cancer tissues, and PPAR-γ ligand induces growth arrest of these cancer cells. In this study, we examined the expression of PPAR-γ in human urological cancer (including renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer) by RT-PCR and immunohistochemistry, and we also examined the effect of PPAR-γ ligand in these cells by MTT assay, flow cytometry and hoechest staining. PPAR-γ expression was significantly more extensive and intense in malignant tissues than in normal tissues. PPAR-γ ligand induced the reduction of malignant cell viability through early apoptosis. These results demonstrated that generated PPAR-γ in urological cancer cells may play an important role in carcinogensis and become a new target therapy in the treatment of urological cancer.
Keywords: Peroxisome proliferator activator-receptor-γ, apoptosis, renal cell carcinoma, bladder tumor, prostate cancer, testicular cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Volume: 9 Issue: 1
Author(s): M. Matsuyama and R. Yoshimura
Affiliation:
Keywords: Peroxisome proliferator activator-receptor-γ, apoptosis, renal cell carcinoma, bladder tumor, prostate cancer, testicular cancer
Abstract: Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to a steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. Up-date, PPAR-γ is expressed in various cancer tissues, and PPAR-γ ligand induces growth arrest of these cancer cells. In this study, we examined the expression of PPAR-γ in human urological cancer (including renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer) by RT-PCR and immunohistochemistry, and we also examined the effect of PPAR-γ ligand in these cells by MTT assay, flow cytometry and hoechest staining. PPAR-γ expression was significantly more extensive and intense in malignant tissues than in normal tissues. PPAR-γ ligand induced the reduction of malignant cell viability through early apoptosis. These results demonstrated that generated PPAR-γ in urological cancer cells may play an important role in carcinogensis and become a new target therapy in the treatment of urological cancer.
Export Options
About this article
Cite this article as:
Matsuyama M. and Yoshimura R., A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/187153009787582432
DOI https://dx.doi.org/10.2174/187153009787582432 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Metabolite Identification in NMR-based Metabolomics
Current Metabolomics The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment
Current Cancer Therapy Reviews Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Controlled Release of Plasmid DNA from Hyaluronan Nanoparticles
Current Drug Delivery Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry The Relationship between Ferroptosis and Tumors: A Novel Landscape for Therapeutic Approach
Current Gene Therapy The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Repeated Restraint and Nerve Growth Factor Administration in Male and Female Mice: Effect on Sympathetic and Cardiovascular Mediators of the Stress Response
Current Neurovascular Research The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Pharmacophore Generation and 3D-QSAR of Novel 2-(quinazolin-4- ylamino)-[1,4] Benzoquinone Derivatives as VEGFR-2 Inhibitors
Letters in Drug Design & Discovery